The Netherlands Cancer Institute: Carcinoma, Non-Small-Cell Lung trials

The registry lists 21 Carcinoma, Non-Small-Cell Lung studies with The Netherlands Cancer Institute as lead sponsor. 5 are open to participants now and 0 have results posted.

Phase 1 3Phase 2 8Phase 3 2No phase 9(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• RADICAL-IO: thRee Cycles of immunotherApy Without raDical Therapy In mediCALly InOperable Stage I Non-small Cell Lung CancerNot yet recruitingNCT07808138Phase 2
• Whole Body HER2 Quantification With 89Zr-Trastuzumab PET/CT to Asses Zr-trastuzumab Accumulation in HER2-mutated and HER2-overexpressing Metastatic Non-small Cell Lung CancerRecruitingNCT07436858Phase 1
• Feasibility of Primer Shot Radiotherapy for Non-small Cell Lung Cancer - PRIMERRecruitingNCT06528743Not applicable
• Whole Body HER3 Quantification With Radiolabelled Patritumab Deruxtecan (HER3-DXd) PET/CTRecruitingNCT06222489Phase 2
• Osimertinib Resistance in Patients With Non-small-cell Lung Carcinoma That Have Progressed.RecruitingNCT04737382Not applicable
• Upfront Resection of Locally Advanced NSCLC Followed by ChemoradiotherapyStatus unknownNCT05620199Not applicable
• Anti-PD-1 Re-challenge After Immune Priming by Ipilimumab and Immune Boosting by Radiotherapy in Advanced NSCLCActive, not recruitingNCT05401786Phase 2
• ctDNA Guided Treatment of Early Resistance to Targeted TreatmentCompletedNCT04148066Not applicable
• Early Response Evaluation in NSCLC Patients Treated With ImmunotherapyTerminatedNCT04082988Not applicable
• T-DM1 and Osimertinib Combination Treatment to Target HER2 Bypass Track Resistance in EGFR Mutation Positive NSCLCTerminatedNCT03784599Phase 2
• Afatinib and Cetuximab in Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion Positive Non-small-cell Lung CancerCompletedNCT03727724Phase 2
• 18F-PD-L1 PET/CT in Nivolumab Treated Patients With NSCLCCompletedNCT03564197Not applicable
• Combination of Platinum Doublets and Hypofractionated Radiotherapy in NSCLCWithdrawnNCT02947113Phase 2
• Lung Cancer Early Molecular Assessment TrialStatus unknownNCT02894853
• Docetaxel Versus Intercalated Erlotinib-docetaxel in Patients With Relapsed EGFR Wild Type, ALK Negative Non Squamous Cell CarcinomaTerminatedNCT02775006Phase 3
• Cisplatin-Pemetrexed Compared With Carboplatin-Paclitaxel-Bevacizumab in KRAS Mutated Non-small Cell Lung CancerStatus unknownNCT02743923Phase 3
• Pembrolizumab After SBRT Versus Pembrolizumab Alone in Advanced NSCLCCompletedNCT02492568Phase 2
• Afatinib and Selumetinib in Advanced KRAS Mutant and PIK3CA Wildtype Non-small Cell Lung CancerStatus unknownNCT02450656Phase 1/2
• An International Study on the Use of PET/CT in Radiotherapy Planning in Low and Middle Income CountriesStatus unknownNCT02247713
• Combined CFRT and SABR in Stage II and III NSCLC With Peripheral Tumors Smaller Than 5 cm.CompletedNCT01933568Phase 1
• Dose Escalation by Boosting Radiation Dose Within the Primary Tumor Using FDG-PET-CT Scan in Stage IB, II and III NSCLCStatus unknownNCT01024829Not applicable